Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases.
Alport syndrome
IgA nephropathy
atopic dermatitis
dupilumab
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
30 Nov 2022
30 Nov 2022
Historique:
received:
01
11
2022
revised:
24
11
2022
accepted:
30
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients' quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings.
Sections du résumé
BACKGROUND
BACKGROUND
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients' quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders.
MATERIALS AND METHODS
METHODS
Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD.
RESULTS
RESULTS
Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment.
CONCLUSION
CONCLUSIONS
Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings.
Identifiants
pubmed: 36556367
pii: life12122002
doi: 10.3390/life12122002
pmc: PMC9785101
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
Dermatol Ther. 2021 Jan;34(1):e14708
pubmed: 33368910
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):958-964
pubmed: 33332697
Kidney Res Clin Pract. 2016 Sep;35(3):147-51
pubmed: 27668157
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36
pubmed: 29471919
Dermatitis. 2022 May-Jun 01;33(3):200-206
pubmed: 35170524
Kidney Blood Press Res. 2021;46(6):659-669
pubmed: 34515143
JAAD Case Rep. 2022 Jan 19;21:150-153
pubmed: 35242969
Clin Exp Nephrol. 2019 Mar;23(3):291-303
pubmed: 30406499
JAAD Case Rep. 2019 Oct 24;5(11):943-944
pubmed: 31700963
Front Med (Lausanne). 2022 Apr 29;9:813313
pubmed: 35573014
Int J Mol Sci. 2021 Oct 14;22(20):
pubmed: 34681722
Clin Exp Dermatol. 2022 Jun;47(6):1191-1193
pubmed: 35167134
Medicines (Basel). 2019 Jun 29;6(3):
pubmed: 31261951
Dermatitis. 2020 Mar/Apr;31(2):e17-e18
pubmed: 32168150